NYSE:TAK Takeda Pharmaceutical (TAK) Stock Price, News & Analysis $16.68 +0.11 (+0.63%) Closing price 03:59 PM EasternExtended Trading$16.70 +0.01 (+0.06%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Takeda Pharmaceutical Stock (NYSE:TAK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Takeda Pharmaceutical alerts:Sign Up Key Stats Today's Range$16.56▼$16.7350-Day Range$16.31▼$18.7752-Week Range$12.99▼$18.90Volume1.87 million shsAverage Volume3.01 million shsMarket Capitalization$53.10 billionP/E Ratio42.78Dividend Yield3.00%Price TargetN/AConsensus RatingModerate Buy Company Overview Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas. Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations. The company concentrates on several core therapeutic areas, including oncology, gastroenterology, neuroscience, rare diseases and plasma-derived therapies, and maintains an active development pipeline aimed at advancing innovative treatments. In addition to internally discovered assets, Takeda has expanded its capabilities and portfolio through strategic acquisitions that broaden its rare-disease and specialty-care offerings. Operating globally, Takeda serves patients and healthcare systems across North America, Europe, Asia and other regions through a network of research sites, manufacturing facilities and commercial offices. Leadership is headed by Christophe Weber, who serves as president and chief executive officer and has overseen the company’s transformation into a global specialty biopharma organization. Takeda emphasizes long-term investment in research and development, strategic collaborations, and patient-focused initiatives as central elements of its corporate strategy.AI Generated. May Contain Errors. Read More Takeda Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreTAK MarketRank™: Takeda Pharmaceutical scored higher than 54% of companies evaluated by MarketBeat, and ranked 561st out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.9 / 5Analyst RatingModerate Buy Consensus RatingTakeda Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageTakeda Pharmaceutical has only been the subject of 3 research reports in the past 90 days.Read more about Takeda Pharmaceutical's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth17.33% Earnings GrowthEarnings for Takeda Pharmaceutical are expected to grow by 17.33% in the coming year, from $1.50 to $1.76 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Takeda Pharmaceutical is 9.64, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.78.Price to Earnings Ratio vs. SectorThe P/E ratio of Takeda Pharmaceutical is 9.64, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.85.Price to Book Value per Share RatioTakeda Pharmaceutical has a P/B Ratio of 1.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Takeda Pharmaceutical's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.16% of the float of Takeda Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverTakeda Pharmaceutical has a short interest ratio ("days to cover") of 1.95, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Takeda Pharmaceutical has recently increased by 5.54%, indicating that investor sentiment is decreasing significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldTakeda Pharmaceutical pays a meaningful dividend of 3.04%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthTakeda Pharmaceutical does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Takeda Pharmaceutical is 128.21%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, Takeda Pharmaceutical will have a dividend payout ratio of 28.41% next year. This indicates that Takeda Pharmaceutical will be able to sustain or increase its dividend.Read more about Takeda Pharmaceutical's dividend. News and Social Media1.9 / 5News Sentiment0.06 News SentimentTakeda Pharmaceutical has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Takeda Pharmaceutical this week, compared to 3 articles on an average week.Search InterestOnly 6 people have searched for TAK on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Takeda Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Takeda Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by Insiders0.04% of the stock of Takeda Pharmaceutical is held by insiders.Percentage Held by Institutions9.17% of the stock of Takeda Pharmaceutical is held by institutions.Read more about Takeda Pharmaceutical's insider trading history. Receive TAK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TAK Stock News HeadlinesBoston jury orders Takeda to pay $885M over delayed generic drug launchMay 19 at 4:55 PM | bizjournals.comAttorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against TakedaMay 18 at 5:51 PM | businesswire.comSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billion - you'd be buying at $1.75 trillion. But one small, publicly traded company sits directly in SpaceX's path, still priced like Wall Street hasn't noticed. It powers the infrastructure Musk's operation can't run without. Dylan Jovine is naming the ticker free - before the June S-1 closes the window.May 20 at 1:00 AM | Behind the Markets (Ad)Takeda engaged in antitrust scheme to delay generic constipation drug, US jury findsMay 18 at 2:53 PM | reuters.comTakeda's Rich Pipeline Optionality Is Worth A 'Buy'May 18 at 7:03 AM | seekingalpha.comTakeda Pharmaceutical (NYSE:TAK) Downgraded to "Buy" Rating by Wall Street ZenMay 16, 2026 | americanbankingnews.comTakeda Pharmaceutical Settles DOJ's Kickback Case for $13.7 MillionMay 14, 2026 | marketwatch.comUS jury to decide if Takeda delayed generic constipation drugMay 14, 2026 | reuters.comSee More Headlines TAK Stock Analysis - Frequently Asked Questions How have TAK shares performed this year? Takeda Pharmaceutical's stock was trading at $15.59 on January 1st, 2026. Since then, TAK stock has increased by 7.0% and is now trading at $16.6850. How were Takeda Pharmaceutical's earnings last quarter? Takeda Pharmaceutical Co. (NYSE:TAK) released its quarterly earnings results on Tuesday, March, 31st. The company reported $0.56 earnings per share for the quarter. The company had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a trailing twelve-month return on equity of 11.07% and a net margin of 4.31%. Does Takeda Pharmaceutical have any subsidiaries? Takeda Pharmaceutical subsidiaries include these companies: PvP Biologics, Shire, TiGenix, ARIAD Pharmaceuticals, Inviragen, LigoCyte Pharmaceuticals, Intellikine, and more. Who are Takeda Pharmaceutical's major shareholders? Takeda Pharmaceutical's top institutional shareholders include Arrowstreet Capital Limited Partnership (0.10%), Renaissance Technologies LLC (0.09%), First Trust Advisors LP (0.06%) and Quantinno Capital Management LP (0.04%). View institutional ownership trends. How do I buy shares of Takeda Pharmaceutical? Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Takeda Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Takeda Pharmaceutical investors own include Johnson & Johnson (JNJ), Meta Platforms (META), Taiwan Semiconductor Manufacturing (TSM), JPMorgan Chase & Co. (JPM), Alibaba Group (BABA), NVIDIA (NVDA) and Pfizer (PFE). Company Calendar Last Earnings3/31/2026Today5/20/2026Next Earnings (Estimated)7/30/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 4 weeks, TAK's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNYSE:TAK CIK1395064 Webwww.takeda.com Phone(166) 204-2111Fax813-3278-2268Employees47,455Year Founded1781Profitability EPS (Trailing Twelve Months)$0.39 Trailing P/E Ratio42.78 Forward P/E Ratio11.12 P/E GrowthN/ANet Income$1.27 billion Net Margins4.31% Pretax Margin5.77% Return on Equity11.07% Return on Assets5.49% Debt Debt-to-Equity Ratio0.56 Current Ratio1.27 Quick Ratio0.70 Sales & Book Value Annual Sales$28.32 billion Price / Sales1.87 Cash Flow$3.12 per share Price / Cash Flow5.34 Book Value$16.12 per share Price / Book1.04Miscellaneous Outstanding Shares3,182,460,000Free Float3,181,185,000Market Cap$53.10 billion OptionableOptionable Beta-0.06 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NYSE:TAK) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredSpaceX did a 5-for-1 split before its IPO - here's whySpaceX just cut its share price from over $526 to roughly $105 with a 5-for-1 stock split - a move that signal...NXT Wave Research | SponsoredFed story no one is tellingJ.P. Morgan's Private Bank quietly advised 333 billionaire families to move 60% of their portfolios into alter...TradeSmith | SponsoredThis stock has 30 days of quiet leftA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...Behind the Markets | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Takeda Pharmaceutical Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Takeda Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
